No abstract available.
Humans ; Intracranial Pressure*

BACKGROUND: Antihistamine drugs are used widely in many conditions. Although some antihistamines may cause a photosensitive reaction,many physicians are not awae of it. OBJECTIVE: For examination of the phototoxic potential of antihistamines, we performed the Candida albiecrns test which is simple, cheap, and good for the screening of many drugs. MEHTODS: Thirty microliters of each solute of various antihistamines were applied to the Sabraud dextrose agar plate in which Candida albicans were applied diffusly. Four hours after the application, 60J/cm fo UVA was irradiated for two days. The irradiated. plates and nonirradiated control ones were incubated in a dark room for 48 hours, and examined for lear zones arround the drug, which means a positive results for the phototoxic potential of the drugs. RESULTS: Mequitazine, thiethylperazine, perphenazine and cllorromazine showed positive results, whereas others did not. An additional Candida albicans test using 0.1%, 0.01%, and 0.001% of the positive drugs revealed tht chlorpromazine, thiethylperazine aderphenazine showed positive results at 0.1%, but negative at 0.01 and 0.001%. Mequitazine was niegative at 0.1, 0.01, and 0,001%, Additional studies of the Candida albicans test using 5% and 10% of the diphenhydramine and dimenhydrinate, those were known photosensitizers but they slowed negative results at this study and revealed very weak posit,ive result in 10% diphenhydramine. CONCLUSION: A photosensitive reaction such as photoallergy and persistent light react,ion may be triggered by the phenothiazine antihistamines. Negative result in 1%, and very weak positive results in 10% diphenhydramine may be due to different mechanism of phototoxicity, or the low phototoxic potential of diphenhydrainine.
Agar ; Candida albicans* ; Candida* ; Chlorpromazine ; Dermatitis, Photoallergic ; Dermatitis, Phototoxic* ; Dimenhydrinate ; Diphenhydramine ; Glucose ; Histamine Antagonists ; Mass Screening* ; Perphenazine ; Photosensitizing Agents ; Thiethylperazine

No abstract available.
Gait*

No abstract available.
DNA*

No abstract available.
Blood Platelets*

PURPOSE: Colposcopic response of preoperative uterine cervix carcinomas to intra-arterial cisplatin infusion chemotherapy was analyzed to evaluate the efficacy of this therapy after selective pelvic arteriography. MATERIALS AND METHODS: Nine patients of stage 1/11 cervical carcinomas were treated twice with intra-arterial cisplatin chemotherapy of a 3-week interval, with every week follow-up of colposcopy and histology until the radical hysterectomy and pelvic lymphadenectomy on the 6th week. Cisplatin of 50mg/m~ was slowly infused via autoinjector for 10 minutes with the catheter tip placed in both internal iliac arteries around uterine artery branching. RESULTS: Colposcopic regression rate of tumor size was as follows:more than 2/3 decrease of original size in 2 patients, 2/3-1/2 in 2 patients, less than 1/2 in 4 patients, but in one patient minimal increase in tumor size was recognized. Colposcopic and postoperative microscopic pathology revealed degeneration and necrosis of the tumor cells and/or adjacent lymph nodes and fibrosis of surrounding tissues. All patients have been doing well until postoperative 25 months without recurrence or significant complications. CONCLUSION: Preoperative intra-arterial cisplatin chemotherapy after selective internal iliac rteriography is helpful to decrease tumor size and improve histologic response and prognosis in stage I and II cervical carcinomas.
Angiography* ; Catheters ; Cervix Uteri* ; Cisplatin* ; Colposcopy ; Drug Therapy* ; Female ; Fibrosis ; Follow-Up Studies ; Humans ; Hysterectomy ; Iliac Artery ; Lymph Node Excision ; Lymph Nodes ; Necrosis ; Pathology ; Prognosis ; Recurrence ; Uterine Artery

No abstract available.
Humans ; Hyperglycemia* ; Infant, Newborn ; Infant, Premature*

BACKGROUND/AIMS: HBcAg is the most immunogenic HBV component and anti-Bc usually persists irrespective of ongoing liver disease or clearance of the virus in human. Therefore anti-Bc is considered as the most sensitive and occasionally the only marker of the HBV infection. Nevertheless, there are a few HBsAg carrier with persistent negative anti-Bc. The epitope which responds to HBcAg is recently defined in HLA A2 from acute viral hepatitis patient due to HBV. So we studied the clinical and laboratory features and nucleotide sequence of HBcAg corresponding to HLA A2 in the HBsAg carrier with persistent negative anti-Bc. METHODS: The subject of these study consists of eight HBsAg chronic carriers with persistent negative anti-Bc. We followed up the clinical features and serological markers of HBV infection and determined the amount of humoral immunoglobulin, HBV DNA and HBcAg when we performed the HLA class I typing and sequencing analysis of core of HBV. Control cases were selected from 3 HLA A2 heterozygote cases with chronic HBsAg carriers with anti-Bc. RESULTS: All subjects had the HBsAg persistently and good health conditions with normal ranges of aminotransferase and humoral immunoglobulin. One of them was converted to anti-Bc-ositive during follow-p period. The level of HBV DNA in serum was higher than 1.2 pg/mL in 7 of 8 chronic HBV carriers. There was a trend of differences between chronic anti-Bc negative carriers and converted one case to anti-Bc positive in the serum of HBcAg and HBV DNA(p=0.06). But strong positive correlation was observed between the amount of HBcAg and HBV DNA in sera. The core portion of HBV was amplified in 4 of 6 HLA A2 heterozygotes by single PCR. When sequenced the PCR products of the above 4 chronic anti-Bc negative HBV carriers and 3 control cases directly, there were no significant difference in the nucleotide and amino acid sequence at the HBcAg epitope which corresopond to class 1 HLA A2. CONCLUSIONS: Our results show that persistent anti-Bc negative chronic HBV carriers may be caused by large amounts of HBV DNA and HBcAg in their sera and not by variants of HBV. These suggested that active viral replication was going on, but are undetectable by the available commercial tests due to binding with excessive amount of HBcAg in the HBV carriers with persistent negative anti-Bc.
Amino Acid Sequence ; Base Sequence* ; DNA ; Hepatitis ; Hepatitis B Core Antigens* ; Hepatitis B Surface Antigens ; Hepatitis B, Chronic* ; Hepatitis, Chronic* ; Heterozygote* ; Humans ; Immunoglobulins ; Liver Diseases ; Polymerase Chain Reaction ; Reference Values

BACKGROUND: Juvenile myoclonic epilepsy(JME) is the most common idiopathic generalized epileptic syndrome which occurs mostly in the second decade of life. It is still frequently unrecognized and misdiagnosed. JME responds well to valproate, but is hardly controlled by other commonly used antiepileptic drug such as carbamazepine or phenytoin. We intended to Investigate the clinical symptoms and EEG findings of JME to support the diagnosis and treatment of JME. SUBJECTS AND METHODS: We retrospectively reviewed the medical record of 18 childrens with JME, from March 1991 to February 1997 We have analysed the clinical symptoms, seizure type, EEG findings including photosensitivity, and the effect of antiepileptic drug. RESULTS: 1) Seven patients were boys and eleven patients were girls(M : F=1 : 1.6). The seizure onset between 5 and 7 years of age were noted in 5 cases, that between 8 and 10 years in 5 cases, and in 8 cases seizures began after 11 years of age 2) Generalized convulsive seizures were noted in 16 cases(GTC 13, GC 2, GCTC 1), myoclonic seizures in 18 cases, absence seizures in 5 cases, and photoconvulsive seizures during video game were associated in 3 cases. 3) Epileptiform discharges at the diagnosis of JME were noted 12 cases(66.7%), and no epileptiform discharges were seen in 6 cases(33.3%). The background activities were normal in all cases. In all 12 cases that showed abnormal epileptiform discharge, generalized spike and wave discharges were obtained, and photosensitivies noted in 4 cases. 4) Follow up EEG obtained after treatment, showed normal EEG findings in 16 cases, and abnormal EEG findings were obtained in 2 cases. 5) Sixteen cases responded well to valproate monotherapy, and 2 other cases responded to valproate and ethosuximide combined therapy. In one case who received vigabatrin, the seizure was aggravated. 6) In 5 cases who discontinued antiepicoptic drug medication after 3 year seizure free duration, 3(60%) cases relapsed within 1 year, and 2(40%) cases remained seizure free for over 1 year. CONCLUSION: Juvenile myoclonic epilepsy is an epileptic syndrome with generalized convulsive seizure, myoclonic seizure, and absence seizure, and EEG findings showed generalized spike and wave discharge in 66.7%, and photosensitivity in 22.2%. JME responded well to valproate monotherapy or valproate and ethosuximide combined the rape, but not responded to other antiepileptic drugs.
Anticonvulsants ; Carbamazepine ; Child ; Diagnosis ; Electroencephalography ; Epilepsy, Absence ; Ethosuximide ; Follow-Up Studies ; Humans ; Medical Records ; Myoclonic Epilepsy, Juvenile* ; Phenytoin ; Rape ; Retrospective Studies ; Seizures ; Valproic Acid ; Video Games ; Vigabatrin

No abstract available.
Cardiomyopathies* ; Congenital Hypothyroidism* ; Echocardiography*